<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1 </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this work was to evaluate the role of <z:chebi fb="0" ids="25029">leukotrienes</z:chebi> in brain damage in vivo in a model of focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in the rat, obtained by permanent occlusion of middle cerebral artery </plain></SENT>
<SENT sid="2" pm="."><plain>2 </plain></SENT>
<SENT sid="3" pm="."><plain>A significant (P &lt; 0.01) elevation of LTC(4), LTD(4) and LTE(4) (<z:chebi fb="0" ids="23511,32460">cysteinyl</z:chebi>-<z:chebi fb="0" ids="25029">leukotrienes</z:chebi>) levels occurred 4 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> induction in the ipsilateral cortices of ischaemic compared to sham-operated animals (3998 +/- 475 and 897 +/- 170 fmol g(-1) tissue, respectively, P &lt; 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>3 </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> MK-801 and the <z:chebi fb="3" ids="16335">adenosine</z:chebi> A(2A) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> SCH 58261 were administered in vivo at doses known to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> size and compared with the <z:chebi fb="0" ids="25029">leukotriene</z:chebi> biosynthesis inhibitor MK-886 </plain></SENT>
<SENT sid="6" pm="."><plain>4 </plain></SENT>
<SENT sid="7" pm="."><plain>MK-886 (0.3 and 2 mg kg(-1) i.v.) and MK-801 (3 mg kg(-1) i.p.) decreased <z:chebi fb="0" ids="23511,32460">cysteinyl</z:chebi>-<z:chebi fb="0" ids="25029">leukotriene</z:chebi> levels (-78%, P &lt; 0.05; -100%, P &lt; 0.01; -92%, P &lt; 0.01, respectively) 4 h after permanent occlusion of the middle cerebral artery, whereas SCH 58261 (0.01 mg kg(-1) i.v.) had no significant effects </plain></SENT>
<SENT sid="8" pm="."><plain>5 </plain></SENT>
<SENT sid="9" pm="."><plain>MK-886 (2 mg kg(-1) i.v.) was also able to significantly reduce the cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 30% (P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>6 </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that <z:chebi fb="0" ids="23511,32460">cysteinyl</z:chebi>-<z:chebi fb="0" ids="25029">leukotriene</z:chebi> formation is associated with <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor activation, and that it represents a neurotoxic event, the inhibition of which is able to reduce brain <z:mpath ids='MPATH_124'>infarct</z:mpath> area in a focal ischaemic event </plain></SENT>
</text></document>